These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 18777649)

  • 1. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking.
    Jin Y; Pollock BG; Coley K; Miller D; Marder SR; Florian J; Schneider L; Lieberman J; Kirshner M; Bies RR
    J Clin Pharmacol; 2010 Jan; 50(1):73-80. PubMed ID: 19843655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to manage the first episode of schizophrenia. Authors did not take account of systemically collected information.
    Crow TJ
    BMJ; 2001 Jan; 322(7280):234-5. PubMed ID: 11159635
    [No Abstract]   [Full Text] [Related]  

  • 3. Introduction to the CATIE special section.
    Swartz MS
    Psychiatr Serv; 2008 May; 59(5):497-9. PubMed ID: 18451004
    [No Abstract]   [Full Text] [Related]  

  • 4. Interpreting the results of the CATIE study.
    Luchins DJ
    Psychiatr Serv; 2006 Jan; 57(1):139-40. PubMed ID: 16399979
    [No Abstract]   [Full Text] [Related]  

  • 5. Selecting antipsychotics in schizophrenia: lessons from CATIE.
    Haddad P; Dursun SM
    J Psychopharmacol; 2006 May; 20(3):332-4. PubMed ID: 16574710
    [No Abstract]   [Full Text] [Related]  

  • 6. [On the question of differences between therapeutic responses after particular neuroleptics in comparison to perphenazine in schizophrenics (author's transl)].
    Náhunek K; Svestka J; Cesková E
    Cesk Psychiatr; 1981 Feb; 77(1):25-30. PubMed ID: 6113897
    [No Abstract]   [Full Text] [Related]  

  • 7. Interpreting the results of the CATIE study.
    Pandiani JA; Banks SM
    Psychiatr Serv; 2006 Jan; 57(1):140-1. PubMed ID: 16399981
    [No Abstract]   [Full Text] [Related]  

  • 8. Revisiting the CATIE schizophrenia study. Although questions remain, some clinical guidance has emerged.
    Harv Ment Health Lett; 2008 Jul; 25(1):1-3. PubMed ID: 18777649
    [No Abstract]   [Full Text] [Related]  

  • 9. The CATIE schizophrenia trial: results, impact, controversy.
    Manschreck TC; Boshes RA
    Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    Citrome L; Stroup TS
    Int J Clin Pract; 2006 Aug; 60(8):933-40. PubMed ID: 16893436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
    Fitzgerald PB
    Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.